Synthetic Biologics Inc. [AMEX: SYN] loss -0.97% or 0.0 points to close at $0.51 with a heavy trading volume of 3132437 shares. The company report on May 6, 2021 that Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results.
Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD.
Initiated Phase 1a Single-Ascending-Dose Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase.
It opened the trading session at $0.51, the shares rose to $0.53 and dropped to $0.49, the range by which the price of stock traded the whole day. The daily chart for SYN points out that the company has recorded 49.41% gains over the past six months. However, it is still -96.15% lower than its most recent low trading price.
If we look at the average trading volume of 9.41M shares, SYN reached to a volume of 3132437 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Synthetic Biologics Inc. [SYN]:
FBR & Co. have made an estimate for Synthetic Biologics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 06, 2017. While these analysts kept the previous recommendation, FBR Capital raised their target price from $10 to $9. The new note on the price target was released on May 06, 2016, representing the official price target for Synthetic Biologics Inc. stock. Previously, the target price had yet another raise to $10, while FBR Capital analysts kept a Outperform rating on SYN stock.
The Average True Range (ATR) for Synthetic Biologics Inc. is set at 0.05 The Price to Book ratio for the last quarter was 0.58, with the Price to Cash per share for the same quarter was set at 0.59.
Trading performance analysis for SYN stock
Synthetic Biologics Inc. [SYN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.36. With this latest performance, SYN shares gained by 2.21% in over the last four-week period, additionally plugging by 49.41% over the last 6 months – not to mention a rise of 58.26% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SYN stock in for the last two-week period is set at 44.65, with the RSI for the last a single of trading hit 46.87, and the three-weeks RSI is set at 44.18 for Synthetic Biologics Inc. [SYN]. The present Moving Average for the last 50 days of trading for this stock 0.6175, while it was recorded at 0.4976 for the last single week of trading, and 0.5573 for the last 200 days.
Synthetic Biologics Inc. [SYN]: A deeper dive into fundamental analysis
Return on Total Capital for SYN is now -113.27, given the latest momentum, and Return on Invested Capital for the company is -87.12. Return on Equity for this stock declined to -89.69, with Return on Assets sitting at -78.32. When it comes to the capital structure of this company, Synthetic Biologics Inc. [SYN] has a Total Debt to Total Equity ratio set at 5.89. Additionally, SYN Total Debt to Total Capital is recorded at 5.56, with Total Debt to Total Assets ending up at 5.62.
Reflecting on the efficiency of the workforce at the company, Synthetic Biologics Inc. [SYN] managed to generate an average of -$1,004,300 per employee.Synthetic Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 37.10 and a Current Ratio set at 37.10.
Synthetic Biologics Inc. [SYN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Synthetic Biologics Inc. posted -0.18/share EPS, while the average EPS was predicted by analysts to be reported at -0.16/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -12.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SYN.
An analysis of insider ownership at Synthetic Biologics Inc. [SYN]
There are presently around $4 million, or 4.50% of SYN stock, in the hands of institutional investors. The top three institutional holders of SYN stocks are: BLACKROCK INC. with ownership of 2,348,372, which is approximately 6045.962% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 2,014,798 shares of the stock with an approximate value of $1.02 million in SYN stocks shares; and MSD PARTNERS, L.P., currently with $0.49 million in SYN stock with ownership of nearly New of the company’s market capitalization.
Positions in Synthetic Biologics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 23 institutional holders increased their position in Synthetic Biologics Inc. [AMEX:SYN] by around 7,952,702 shares. Additionally, 4 investors decreased positions by around 1,340,922 shares, while 7 investors held positions by with 836,146 shares. The mentioned changes placed institutional holdings at 8,457,478 shares, according to the latest SEC report filing. SYN stock had 13 new institutional investments in for a total of 2,207,060 shares, while 3 institutional investors sold positions of 1,326,227 shares during the same period.